The Etiological Features and Treatment of Vitiligo: A Pilot Study Prospective to Indian Scenario

Kailash P. Jaiswal¹ , Anil Sarsavan² , Ram Kumar Chaudhary³ , Sharique A Ali⁴ , Manoj K Tembre⁵

Section:Survey Paper, Product Type: Isroset-Journal
Vol.1 , Issue.1 , pp.10-17, Jan-2014

Online published on Feb 28, 2014

Copyright © Kailash P. Jaiswal, Anil Sarsavan, Ram Kumar Chaudhary, Sharique A Ali , Manoj K Tembre . This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 

View this paper at   Google Scholar | DPI Digital Library

XML View     PDF Download

How to Cite this Paper

Abstract :
Despite studies of Vitiligo pathogenesis still evades its exact pathway, causes, a cast effective therapy challenge for Indian. Vitiligo is an acquired disorder of pigmentation, caused by decreased production of melanin as a result of dysfunction of melanocytes. In Indian tradition system plants medicine using for treatment of leucoderma but still no effective medicine cure the vitiligo. Indian studies of vitiligo find higher prevalence of vitiligo in Gujarat, Rajasthan, Madhya Pradesh, main possible causes are genetic, cellular, triggering, environmental effects, these gene polymorphism of candidate gene that are part of the immune system or part of melanocytes have both been associated with vitiligo and other autoimmune disorders. Environment Pollution like water, air and food pollution effects human health and increasing in villages and cities of India, environment pollution management and some diseases still gap in knowledge which are challenge for India.

Key-Words / Index Term :
Autoimmunity; Etiology, Gene Polymorphism, Genetic Susceptibility, Melanocyte, Pigmentation, Vitiligo, ACE, Neural Factors, Oxidative Stress, Vitiligo Associated Disorders Idiopathic Achroma

References :
[1]. Anupama Sharma2, Sanjeev Kumar Singh2 and S. D. Tonpay3, Ethano medicinal trends in Indian tradition for treatment of vitiligo, Journal of Medicinal Plants Research, 2012,Vol. 6(10), pp. 1827-1833.
[2]. Birlea S A, Ahmad F J, Uddin R M et al. J Invest Dermatol 2013.doi:10.1038/,jid.
[3]. Casp1, J-X She1, 2 and WT McCormack1, Genes of the LMP/TAP cluster are associated with the human autoimmune disease vitiligo, Genes and Immunity, 2003,issue- 4,pp, 492–499.
[4]. Chang H Y et al. Proc Natl Acad Sci U S A, 2002: issue-99: pp.12877–12882.
[5]. Chang H Y. J Invest Dermatol, 2007: issue-127:pp. 994–995.
[6]. Dunston G M, Halder R M. Arch Dermatol, 1990: issue-126:pp. 56–60.
[7]. Dwivedi M, Laddha N C, Imran M et al. Pigment Cell Melanoma Res, 2011: issue-24:pp. 737–740.
[8]. Esposito M, Soda R, Costanzo A, Chimenti S Treatment of vitiligo with the 308 nm excimer laser. Clinical and Experimental Dermatology 2004; 29: 133–137.
[9]. Farha Deeba¹, Kaiser Jamil², Syed Rabbani², M.A.Waheed³ and Hanmanth Rao¹,Association of angiotensin converting enzyme gene I/Dpolymorphism with vitiligo in South Indian population, International Journal of Medicine and Medical Sciences, 2009, Vol.1 (1) pp. 009-012.
[10]. Grimes PE,white paches and bruised souls: Advance in Pathogenesis and treatment of Vitiligo, J AM Acad, Dearmetal ,2004;issue-1;pp.5-7.
[11]. Gude Dilip,Vitiligo:never inshite pathophysiologyand treatment,Indian journal of ped. Dermatology, 2012, vol-13; issue-1, pp.87-92.
[12]. Handa S, Kaur. Vitiligo: clinical findings in 1436 patients, J Dermatol.1999; issue-10: pp.653 I
[13]. Hani A. Al Shobaili, Updates on the genetic characterization of vitiligo, International Journal of Health Sciences, Qassim University, 2011, Vol. 5, No. 2, pp.1432.
[14]. Kemp E H et al. Clin Exp Immunol 2001: issue-124: pp.509–515.
[15]. Laddha N C, Dwivedi M, Shajil E M et al. J Dermatol Sci, 2008: issue-49: 260–262.
[16]. Lerner, AB. Vitiligo. Journal of Investigative Dermatology, 1959, Vol. 32, No. 2, pp.285-310.
[17]. Majumder, PP., Das, SK., Li, CC., Genetical Model for Vitiligo. American Journal of Human Genetics, 1988, Vol. 43, No. 2, pp. 119-25.
[18]. Mehta N R, Shah K C, Theodore C, Vyas V & Patel A, Epidemiological study of vitiligo in Surat area, South Gujarat, Indian J Med Res, 1973, issue-61 pp. 145.
[19]. Mollet I, Onqenae K, Naeyaert JM. Origin, clinical presentation, and diagnosis of hypomelanotic skin disorders. Dermatol. Clin, 2007; issue- 25(3):pp.363-371.
[20]. Naresh C. Laddha1, Mitesh Dwivedi1, Mohmmad S. Mansuri1, Amina R. Gani1, Md Ansarullah2, Vitiligo: interplay between oxidative stress and immune system, DOI: 10.1111/exd.12103.
[21]. Nath, SK., Majumder, PP., Nordlund, JJ. (1994). Genetic epidemiology of vitiligo: multilocus recessivity cross-validated. American Journal of Human Genetics, 1994, Vol. 55, No. 5, pp.981-90.
[22]. Ogg G S et al. J Exp Med 1998: issue-188: pp.1203–1208.
[23]. Ortonne JP, Bose SK. Vitiligo 8: Where do we stand? Pigment Cell Res.1993; issue- 61:pp. 653.
[24]. Poole IC, Luiten RM, Autoimmune etiology of generalized, 2008.
[25]. Richard A Spritz. The genetics of generalized vitiligo: autoimmune pathways and an inverse relationship with malignant melanoma, Spritz Genome Medicine, 2010, issue-2:pp.78.
[26]. Richard A. Spritz, Six decades of vitiligo genetics: Genome wide studies provide insights into autoimmune pathogenesis, J Invest Dermatol. 2012; issue- 132(2):pp. 268–273.
[27]. Richard A. Spritz, The genetics of generalized vitiligo and associated, 2007, Pigment Cell Res. Issue-20; pp.271–278.
[28]. Rinn J L et al. PLoS Genet 2006; issue- 2: pp.119.
[29]. Schallreuter K U et al. J Invest Dermatol, 1991; issue- 97:pp. 1081–1085.
[30]. Schallreuter K U, Wood J M. J Photochem Photobiol, 2001; issue- 64:pp. 179–184.
[31]. Schallreuter, Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, 2007, DOI:10.1111/j.pp.1600-0625.
[32]. Shajil E M, Agrawal D, Vagadia K et al. Indian J of Dermatol 2006; issue- 51:pp. 100–104.
[33]. Sharma Girish Chandra1, Anupama Sharma2, Sanjeev Kumar Singh2 and S. D. Tonpay3, Ethanomedicinal trends in Indian tradition for treatment of vitiligo, Journal of Medicinal Plants Research, 2012, Vol. 6(10), pp. 1827-1833.
[34]. Singh A, Sharma P, Kar H K et al. J Invest Dermatol, 2012; issue- 132:pp. 124–134.
[35]. Singh A, Sharma P, Kar H K et al. J Invest Dermatol, 2012; issue- 132: pp.124–134.
[36]. Spritz R A. Curr Dir Autoimmunity, 2008; issue- 10:pp. 244–257.
[37]. Taieb, A. Alomar, M. Böhm, M.L. Dell'Anna, A. De Pase, V. Eleftheriadou, K. Ezzedine, Y. Gauthier, D.J. Gawkrodger, T. Jouary, G. Leone, S. Moretti, L. Nieuweboer-Krobotova, M.J. Olsson, D. Parsad, T. Passeron, A. Tanew, W. van der Veen, N. van Geel, M. Whitton, A. Wolkerstorfer, M. Picardo, Guidelines for the Management of Vitiligo, The British Journal of Dermatology. 2013; issue-168(1):pp.5-19.
[38]. Tobin D J et al. J Pathol, 2000; issue- 191: pp.407–416.
[39]. Valia A K & Dutta P K, IADVL Text book and atlas of dermatology, 1996; issue- 10: pp.227-243.
[40]. Wolff, K., Johnson, RA., Pigmentary Disorders, In: Fitzpatrick’s Color Atlas &Synopsis of Clinical Dermatology, 2009, pp. 518.
[41]. Wood J M, Schallreuter K U. J Invest Dermatol 2006: issue-126:pp. 13–14.
[42]. Zabawski EJ, Costner M, Cohen JB, Cockerell CJ. Tacrolimus:pharmacology and therapeutic uses in dermatology. Int. J. Dermatol 2000; 39:721–7.
[43]. Spritz, the genetics of generalized vitiligo: autoimmune pathways and an inverse relationship with malignant melanoma,,Genome Medicine 2010,issue- 2:pp.78.